FY2026 Earnings Estimate for KROS Issued By Leerink Partnrs

Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Research analysts at Leerink Partnrs increased their FY2026 EPS estimates for shares of Keros Therapeutics in a research report issued to clients and investors on Thursday, February 27th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings per share of ($4.66) for the year, up from their prior forecast of ($4.86). The consensus estimate for Keros Therapeutics' current full-year earnings is ($4.74) per share. Leerink Partnrs also issued estimates for Keros Therapeutics' FY2027 earnings at ($4.16) EPS, FY2028 earnings at ($1.95) EPS and FY2029 earnings at ($2.60) EPS.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share for the quarter, topping the consensus estimate of ($1.36) by $0.22. The company had revenue of $3.04 million for the quarter, compared to the consensus estimate of $37.32 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%.

KROS has been the subject of several other research reports. William Blair lowered shares of Keros Therapeutics from an "outperform" rating to a "market perform" rating in a report on Thursday, December 12th. Wells Fargo & Company lowered their target price on shares of Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, February 27th. HC Wainwright dropped their target price on shares of Keros Therapeutics from $47.00 to $40.00 and set a "buy" rating for the company in a report on Thursday, February 27th. Oppenheimer decreased their price target on shares of Keros Therapeutics from $63.00 to $23.00 and set an "outperform" rating on the stock in a research note on Thursday, January 16th. Finally, Truist Financial lowered their price objective on Keros Therapeutics from $100.00 to $43.00 and set a "buy" rating on the stock in a research note on Monday, December 23rd. Six research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, Keros Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $42.33.

Remove Ads

Keros Therapeutics Price Performance

KROS stock traded up $0.20 during mid-day trading on Monday, reaching $11.87. 186,338 shares of the company's stock were exchanged, compared to its average volume of 1,549,683. Keros Therapeutics has a 12-month low of $9.77 and a 12-month high of $72.37. The stock's 50 day moving average is $12.20 and its 200 day moving average is $38.82. The company has a market cap of $481.47 million, a price-to-earnings ratio of -2.27 and a beta of 1.39.

Hedge Funds Weigh In On Keros Therapeutics

Hedge funds have recently bought and sold shares of the company. AlphaQuest LLC boosted its holdings in shares of Keros Therapeutics by 469.0% in the 4th quarter. AlphaQuest LLC now owns 3,596 shares of the company's stock valued at $57,000 after buying an additional 2,964 shares during the period. Virtus ETF Advisers LLC boosted its stake in Keros Therapeutics by 107.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company's stock valued at $61,000 after purchasing an additional 1,998 shares during the period. KBC Group NV grew its stake in shares of Keros Therapeutics by 52.0% in the third quarter. KBC Group NV now owns 1,263 shares of the company's stock worth $73,000 after purchasing an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Keros Therapeutics by 26.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company's stock worth $77,000 after purchasing an additional 280 shares in the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of Keros Therapeutics during the fourth quarter valued at $90,000. 71.56% of the stock is currently owned by institutional investors and hedge funds.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.